The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Antitumor Immunity

• Published in: Cancer immunology research Vol. 12; no. 6; p. 663
• Main Authors: Lim, Junghyun, Rodriguez, Ryan, Williams, Katherine, Silva, John, Gutierrez, Alan G, Tyler, Paul, Baharom, Faezzah, Sun, Tao, Lin, Eva, Martin, Scott, Kayser, Brandon D, Johnston, Robert J, Mellman, Ira, Delamarre, Lélia, West, Nathaniel R, Müller, Sören, Qu, Yan, Heger, Klaus
• Format: Journal Article
• Language: English
• Published: United States 04.06.2024
• Subjects: Animals; CD8-Positive T-Lymphocytes - immunology; CD8-Positive T-Lymphocytes - metabolism; Cell Line, Tumor; Exodeoxyribonucleases - genetics; Exodeoxyribonucleases - metabolism; Humans; Immune Checkpoint Inhibitors - pharmacology; Immune Checkpoint Inhibitors - therapeutic use; Immunity, Innate; Interferon Type I - metabolism; Membrane Proteins - genetics; Membrane Proteins - metabolism; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasms - genetics; Neoplasms - immunology; Neoplasms - metabolism; Nucleotidyltransferases - genetics; Nucleotidyltransferases - metabolism; Phosphoproteins - genetics; Phosphoproteins - metabolism; Signal Transduction
• ISSN: 2326-6074
• DOI: 10.1158/2326-6066.CIR-23-1078

The DNA exonuclease three-prime repair exonuclease 1 (TREX1) is critical for preventing autoimmunity in mice and humans by degrading endogenous cytosolic DNA, which otherwise triggers activation of the innate cGAS/STING pathway leading to the production of type I IFNs. As tumor cells are prone to aberrant cytosolic DNA accumulation, we hypothesized that they are critically dependent on TREX1 activity to limit their immunogenicity. Here, we show that in tumor cells, TREX1 restricts spontaneous activation of the cGAS/STING pathway, and the subsequent induction of a type I IFN response. As a result, TREX1 deficiency compromised in vivo tumor growth in mice. This delay in tumor growth depended on a functional immune system, systemic type I IFN signaling, and tumor-intrinsic cGAS expression. Mechanistically, we show that tumor TREX1 loss drove activation of CD8+ T cells and NK cells, prevented CD8+ T-cell exhaustion, and remodeled an immunosuppressive myeloid compartment. Consequently, TREX1 deficiency combined with T-cell-directed immune checkpoint blockade. Collectively, we conclude that TREX1 is essential to limit tumor immunogenicity, and that targeting this innate immune checkpoint remodels the tumor microenvironment and enhances antitumor immunity by itself and in combination with T-cell-targeted therapies. See related article by Toufektchan et al., p. 673.